Informed Consent Formats by Information Preference and Priority

January 24, 2018 updated by: Carnegie Mellon University
This study will test whether different formats of medical informed consent documents can help improve understanding and confidence in decision-making for clinical trials. The study will be primarily run through an online survey.

Study Overview

Detailed Description

The goal of this study is to investigate whether the same information can be communicated in different formats of an informed consent document in ways that improve participant understanding and confidence. Participants will review one of several different versions of the same informed consent document, and will be asked to complete a survey after reading the documents. The survey will ask participants their willingness to enroll in the clinical trial discussed in the document and their confidence in their decision. The survey will also test participants recollection of information from the informed consent document. Researchers will look at this data to see if there are ways to improve knowledge about the clinical trial and confidence in decisions without necessarily changing enrollment preferences.

Study Type

Interventional

Enrollment (Actual)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • Carnegie Mellon University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 Years Old or Older
  • Read and agreed to informed consent
  • Indicated desire to participate
  • Diagnosed with asthma
  • US resident

Exclusion Criteria:

  • Participants from whom we receive multiple responses will be dropped from analysis (but will be compensated for participation)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Original
Participants will review the full-length, original consent form for the clinical trial.
Participants will review the full-length, original consent form for the clinical trial.
Experimental: Shortened
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
Experimental: Reordered
Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
Experimental: Highlighted
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
Experimental: Interactive
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Score for high impact questions
Time Frame: through study completion, an average of 30 minutes
Sum of correct answers (T/F) for any item relating to material that was rated as 50 or higher on impact on willingness to enroll in a previous study.
through study completion, an average of 30 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Score for low impact questions
Time Frame: through study completion, an average of 30 minutes
Sum of correct answers (T/F) for any item relating to material that was rated as 49 or lower on impact on willingness to enroll in a previous study.
through study completion, an average of 30 minutes
Total score for all questions
Time Frame: through study completion, an average of 30 minutes
Sum of correct answers (T/F) on full knowledge test.
through study completion, an average of 30 minutes
Interaction effect of format and importance on likelihood of correct answer
Time Frame: through study completion, an average of 30 minutes
Interaction effect in a logistic regression predicting a correct answer, based on the format of the consent form and the importance of the answer.
through study completion, an average of 30 minutes
Scores for different information categories
Time Frame: through study completion, an average of 30 minutes
Sum of correct answers (T/F) for each of the 20 information categories
through study completion, an average of 30 minutes
Effect of location on score
Time Frame: through study completion, an average of 30 minutes
Logistic regression coefficient of likelihood of predicting a correct answer, based upon the location on which the sentence appeared--uses only the shortened, and the reordered conditions. Note that sentences appearing in the introduction (which is the first section of all treatments) must be dropped, as there will be no variation in location.
through study completion, an average of 30 minutes
Decision to enroll
Time Frame: through study completion, an average of 30 minutes
Likert measure of participants hypothetical decision to enroll in the study
through study completion, an average of 30 minutes
Confidence in enrollment decision
Time Frame: through study completion, an average of 30 minutes
Likert measure of participants confidence in hypothetical decision to enroll in the study
through study completion, an average of 30 minutes
Satisfaction with consent structure
Time Frame: through study completion, an average of 30 minutes
Likert measure of participants satisfaction with the consent form
through study completion, an average of 30 minutes
Perception of investigator concern for well being
Time Frame: through study completion, an average of 30 minutes
Likert measure of participants belief in the investigator's concerns for the participant's well-being
through study completion, an average of 30 minutes
Perception of investigator transparency
Time Frame: through study completion, an average of 30 minutes
Likert measure of participants belief that the investigator is trying to communicate information about the trial accurately
through study completion, an average of 30 minutes
Participant's probability estimate of the likelihood that the treatment would help control their asthma
Time Frame: through study completion, an average of 30 minutes

Survey question of the following form:

'If you enrolled in the trial described in the consent form, what is the probability that the treatment could help control your asthma better, where 0% means "no chance at all of helping" and 100% means "would definitely help"?'

Participants provided with drop-down menu including values from 0% to 100% in increments of 1%.

through study completion, an average of 30 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant's free-response text describing what was learned from reading the informed consent document
Time Frame: through study completion, an average of 30 minutes

Survey question of the following form:

"What are some of the key things you learned from reading the informed consent document?"

Participants are then provided with an free-response text box where they are allowed to enter whatever text they want, as long as they enter some text. These responses will be coded by two independent coders, blinded to the treatment arms, using an emergent coding system to identify different topics that participants may raise.

through study completion, an average of 30 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 27, 2017

Primary Completion (Actual)

December 31, 2017

Study Completion (Actual)

December 31, 2017

Study Registration Dates

First Submitted

January 8, 2018

First Submitted That Met QC Criteria

January 24, 2018

First Posted (Actual)

January 31, 2018

Study Record Updates

Last Update Posted (Actual)

January 31, 2018

Last Update Submitted That Met QC Criteria

January 24, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • STUDY2017_00000268

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Intend to share deidentified participant data, but we want to review the received data to ensure that there is no information that could potentially reveal individual identity that we may not initially anticipate. As such, a clear delineation of what data will be disclosed is not yet available.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on Original consent form

3
Subscribe